Official Title
An Adaptive, Randomized, Double-blind, Parallel-controlled Clinical Trial of Yinhu Qingwen Granula for the Treatment of Severe CoVID-19
Brief Summary

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.Given no specific antiviral therapy for CoVID-19 infection and the availability of Yinhu Qingwen Granula as a potential antiviral Chinese medicine based on vivo antiviral studies in CoVID-19, this adaptive, randomized,double-blind,controlled trial will evaluate the efficacy and safety of Yinhu Qingwen Granula in patients hospitalized with severe CoVID-19.

Detailed Description

In December 2019, Wuhan, in Hubei province, China, became the center of an outbreak of pneumonia caused by CoVID-19, and the number of cases of infection with CoVID-19 identified in Wuhan increased markedly over the later part of January 2020, with cases identified in multiple other Provinces of China and internationally.The clinical spectrum of CoVID-19 infection appears to be wide,including asymptomatic infection, mild upper respiratory disease, severe viral pneumonia with respiratory failure, and even death. However,there is no specific antiviral therapy for CoVID-19 infection, which provides a window of opportunity for testing candidate antiviral therapies. Previous experiences with SARS and MERS-CoV, highlight the need of the early intervention with Chinese medicine, and so as for CoVID-19 infection. The treatment of Chinese medicine for CoVID-19 infection suggested its benefits to improve of clinical outcomes, reduce the risk of disease progression, accelerate recovery, and reduce intensive supportive care and long-term hospitalization.Yinhu Qingwen Granula was a kind of herbal granula made from "Yinhu Qingwen Decoction", which consists of 11 common non-toxic traditional Chinese medicine such as Polygonum cuspidatum, Honeysuckle, Nepeta, Ligustrum lucidum. Previous vivo antiviral studies showed its activity for the inbition of CoVID-19. This clinical trial is planned to evaluate the improvement of the changes in the ratio of PaO2 to FiO2 from the baseline for patients with severe CoVID-19 as the primary outcome, and to evaluate the effect of the symptoms relief and virus clearance as well as the clinical safety.

Not yet recruiting
COVID-19
Severe Pneumonia
Chinese Medicine

Drug: Yinhu Qingwen Granula
Yinhu Qingwen Granula is a kind of herbal granula made from "Yinhu Qingwen Decoction", which consits of 11 Chinese herbal medicine as Honeysuckle, Polygonum cuspidatum, Schizonepeta, Longspur epimedium, etc. The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml). It will be given a 200ml per time, three times a day, for 10 days.
Yinhu Qingwen Granula Group

Drug: Yin Hu Qing Wen Granula(low does)
This intervention is given as 10% dose of YinHu QingWen Granula.The granula will be dissolved into 600ml decoction and divided to 3 times (once with 200ml).
Yinhu Qingwen Granula Low-dose Group

Other: standard medical treatment
Standard medical treatment is adhered to the protocol of the treatment for the severe CoVID-19 according to the guideline approved by National Health Commission of China.
Yinhu Qingwen Granula Group
Yinhu Qingwen Granula Low-dose Group

Eligibility Criteria

Inclusion Criteria:

1. Age ≥18 years at time of signing Informed Consent Form;

2. Those who meet the diagnosis of severe new coronavirus pneumonia with laboratory confirmed infection with CoVID-19;

3. Lung involvement confirmed with chest imaging;

4. Hospitalized with a Pa02/Fi02 ratio ≤300mgHg;

5. 40%> lymphocyte percentage ≥5%;

6. No difficulty swallowing oral medications.

Exclusion Criteria:

1. Allergies, those who are known to be allergic to research drugs or drug excipients;

2. The patient weighs less than 40 kg;

3. Patients with diarrhea;

4. Shock;

5. Patients with respiratory failure at the time of enrollment who need invasive mechanical ventilation;

6. The clinician judges that ICU admission is needed;

7. Patients who participated in other clinical trials within 1 month;

8. Known patients with impaired renal function (estimated creatinine clearance 5 times the upper limit of normal range (ULN) or ALT or AST level> 3 times ULN and total bilirubin levels> 2 times ULN;

10. Being pregnant or breastfeeding, or having a positive pregnancy test at the time of pre-dose inspection, or planning to become pregnant within 3 months after study treatment;

11. Will be transferred to another hospital which is not the study site within 72 hours.

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years
Countries
China
Contacts

Jun Liu, M.D.
8610-64093207
franlj1104@aliyun.com

Dong Shang, M.D.
Principal Investigator
Wuhan Leishenshan (Thunder God Mountain) Hospital/The First Affiliated Hospital of Dalian Medical University

~

Jiang-Rong Huang, M.D.
Principal Investigator
Yangtze University Health Science Center

~

Xiao-Dong Li, M.D.
Principal Investigator
Hubei Hospital of Traditional Chinese Medicine

~

Zhong Wang, M.D.
Study Director
China Academy of Chinese Medical Sciences

Zhong Wang
Wuhan Leishenshan Hospital
The First Affiliated Hospital of Dalian Medical University
Tanshan People's Hospital
North China University of Science and Technology Affiliated Hospital
Jizhong Energy Fengfeng Group Hospital
NCT Number
MeSH Terms
Pneumonia